Oppenheimer Asset Management Inc. Has $31.35 Million Stock Position in Novo Nordisk A/S $NVO

Oppenheimer Asset Management Inc. grew its position in Novo Nordisk A/S (NYSE:NVO) by 14.4% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 565,007 shares of the company’s stock after purchasing an additional 71,283 shares during the period. Oppenheimer Asset Management Inc.’s holdings in Novo Nordisk A/S were worth $31,352,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Werba Rubin Papier Wealth Management increased its position in Novo Nordisk A/S by 4.1% during the second quarter. Werba Rubin Papier Wealth Management now owns 4,378 shares of the company’s stock worth $302,000 after buying an additional 173 shares during the last quarter. Beacon Financial Group lifted its holdings in Novo Nordisk A/S by 4.3% in the 3rd quarter. Beacon Financial Group now owns 4,307 shares of the company’s stock worth $239,000 after purchasing an additional 178 shares during the last quarter. Revolve Wealth Partners LLC grew its holdings in Novo Nordisk A/S by 8.7% during the fourth quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock valued at $214,000 after purchasing an additional 200 shares during the last quarter. Kavar Capital Partners Group LLC lifted its stake in shares of Novo Nordisk A/S by 0.6% in the third quarter. Kavar Capital Partners Group LLC now owns 32,631 shares of the company’s stock worth $1,811,000 after buying an additional 200 shares during the last quarter. Finally, SeaBridge Investment Advisors LLC grew its position in shares of Novo Nordisk A/S by 5.7% in the third quarter. SeaBridge Investment Advisors LLC now owns 3,735 shares of the company’s stock valued at $207,000 after purchasing an additional 200 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Stock Up 10.1%

NVO opened at $47.71 on Monday. The firm’s 50-day simple moving average is $53.61 and its 200-day simple moving average is $53.73. The company has a debt-to-equity ratio of 0.61, a quick ratio of 0.57 and a current ratio of 0.80. Novo Nordisk A/S has a twelve month low of $43.08 and a twelve month high of $93.80. The firm has a market cap of $213.03 billion, a price-to-earnings ratio of 13.75 and a beta of 0.67.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $1.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.90 by $0.11. The firm had revenue of $12.43 billion during the quarter, compared to the consensus estimate of $11.97 billion. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. Equities research analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Announces Dividend

The firm also recently announced a dividend, which will be paid on Wednesday, April 8th. Stockholders of record on Monday, March 30th will be issued a $1.2751 dividend. This represents a dividend yield of 541.0%. The ex-dividend date of this dividend is Monday, March 30th. Novo Nordisk A/S’s payout ratio is presently 52.74%.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on NVO. Citigroup initiated coverage on Novo Nordisk A/S in a research report on Tuesday, January 27th. They issued a “neutral” rating for the company. The Goldman Sachs Group restated a “buy” rating on shares of Novo Nordisk A/S in a research note on Thursday, January 22nd. Zacks Research raised Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a report on Friday, January 9th. BMO Capital Markets restated a “market perform” rating on shares of Novo Nordisk A/S in a research note on Thursday. Finally, TD Cowen reiterated a “buy” rating on shares of Novo Nordisk A/S in a research note on Tuesday, February 3rd. Seven investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $56.07.

Key Stories Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: FDA says it will target mass-marketed, unapproved compounded drug copies, which reduces the competitive threat from low-cost copycats and helped lift sentiment. Novo Nordisk shares rebound as FDA targets illegal drug copies – Reuters
• Positive Sentiment: Some analysts view the recent selloff as overdone and argue NVO’s strong cash flow, first-mover Wegovy advantages and promising pipeline (CagriSema) make the pullback a buying opportunity for long-term holders. Novo Nordisk: The Selloff Is A Blessing In Disguise – Seeking Alpha
• Positive Sentiment: Novo has announced it will pursue legal action against Hims & Hers over compounded Wegovy copies — a defensive step that could limit spread of low-cost alternatives if successful. Novo Nordisk to take legal action against Hims & Hers for Wegovy compounding – Reuters
• Neutral Sentiment: Company disclosure shows trading by board members and executives — useful for monitoring insider behavior but not immediately directional. Trading in Novo Nordisk shares by board members, executives – GlobeNewswire
• Neutral Sentiment: Company declared a dividend (record/ex-dividend dates published) — supportive for income investors but not a cure for near-term volume/price headwinds.
• Negative Sentiment: Hims & Hers launched a $49–$99 compounded oral semaglutide offering, sharply undercutting Wegovy’s price and triggering market panic about pricing erosion and access to cheap compounding alternatives. Hims and Hers Health launches copy of Wegovy pill at $49 – Reuters
• Negative Sentiment: Citi warns that inability to curb compounded semaglutide use is a lingering risk to Novo’s pricing power and investor sentiment. Citi flags lingering risks to Novo despite strong weight-loss portfolio – Proactive Investors
• Negative Sentiment: Competitive dynamics: Eli Lilly’s strong guidance and manufacturing scale are shifting market share and investor preference toward Lilly, increasing near-term pressure on Novo’s revenue outlook. The Metabolic Split: Why Eli Lilly Soars as Novo Stumbles – MarketBeat
• Negative Sentiment: Regional weakness: Ozempic sales in greater China fell for the first time, highlighting geographic and competitive pressures. Novo reports first Ozempic sales drop in greater China region – Reuters

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.